Shunsuke Sami
Direktor/Vorstandsmitglied bei GenomIdea, Inc.
Aktive Positionen von Shunsuke Sami
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GenomIdea, Inc.
GenomIdea, Inc. BiotechnologyHealth Technology Part of ISHIHARA SANGYO KAISHA LTD., GenomIdea, Inc. engages in biopharmaceutical products development and distribution. The company is based in Ibaraki, Japan. GenomIdea was acquired by ISHIHARA SANGYO KAISHA LTD. from AnGes, Inc. on January 31, 2013 for $0.0 million. | Direktor/Vorstandsmitglied | 01.03.2009 | - |
Karriereverlauf von Shunsuke Sami
Ehemalige bekannte Positionen von Shunsuke Sami
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ANGES, INC. | Direktor/Vorstandsmitglied | 01.09.2008 | - |
Corporate Officer/Principal | 01.09.2008 | - | |
AnGes USA, Inc.
AnGes USA, Inc. Pharmaceuticals: MajorHealth Technology Part of AnGes, Inc., AnGes USA, Inc. develops and manufactures medicines. The company is based in Gaithersburg, MD. Ei Yamada has been the CEO of the company since 2014. | Vorstandsvorsitzender | 22.03.2011 | - |
IMMD, Inc.
IMMD, Inc. BiotechnologyHealth Technology IMMD, Inc. provides drug discovery research for pharmaceutical companies. It identifies drug seeds by virtual screening, to select promising seeds and to optimize the seeds by minimum syntheses, based on estimated docking mode to the target. The firm also establishes a drug discovery method using software system for rational drug design based on 3-D structures of target proteins. Its business activities also include collaborative drug discovery researches, in-house drug discovery program, and drug seeds. The company was founded by Akiko Itai on March 16, 1995 and is headquartered in Tokyo, Japan. | Corporate Officer/Principal | 01.05.2007 | - |
Bristol-Myers Squibb KK
Bristol-Myers Squibb KK BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb KK develops, manufactures and markets biopharmaceutical products. The company is based in Shinjuku-ku, Japan. | Direktor/Vorstandsmitglied | 01.01.2008 | - |
Corporate Officer/Principal | 01.01.2008 | - | |
SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | 01.04.1984 | - |
Statistik
International
Japan | 6 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 7 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SUMITOMO PHARMA CO., LTD. | Health Technology |
ANGES, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
IMMD, Inc.
IMMD, Inc. BiotechnologyHealth Technology IMMD, Inc. provides drug discovery research for pharmaceutical companies. It identifies drug seeds by virtual screening, to select promising seeds and to optimize the seeds by minimum syntheses, based on estimated docking mode to the target. The firm also establishes a drug discovery method using software system for rational drug design based on 3-D structures of target proteins. Its business activities also include collaborative drug discovery researches, in-house drug discovery program, and drug seeds. The company was founded by Akiko Itai on March 16, 1995 and is headquartered in Tokyo, Japan. | Health Technology |
Bristol-Myers Squibb KK
Bristol-Myers Squibb KK BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb KK develops, manufactures and markets biopharmaceutical products. The company is based in Shinjuku-ku, Japan. | Health Technology |
AnGes USA, Inc.
AnGes USA, Inc. Pharmaceuticals: MajorHealth Technology Part of AnGes, Inc., AnGes USA, Inc. develops and manufactures medicines. The company is based in Gaithersburg, MD. Ei Yamada has been the CEO of the company since 2014. | Health Technology |
GenomIdea, Inc.
GenomIdea, Inc. BiotechnologyHealth Technology Part of ISHIHARA SANGYO KAISHA LTD., GenomIdea, Inc. engages in biopharmaceutical products development and distribution. The company is based in Ibaraki, Japan. GenomIdea was acquired by ISHIHARA SANGYO KAISHA LTD. from AnGes, Inc. on January 31, 2013 for $0.0 million. | Health Technology |
- Börse
- Insiders
- Shunsuke Sami
- Erfahrung